RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial…
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial…
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the…
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the…
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least…
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least…
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net…
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net…
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline…
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline…
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase…
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase…
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…